Citius Pharmaceuticals: From Development Stage to Commercial Oncology – A Live Discussion with CEO Leonard Mazur
Wednesday, March 11, 2026
11:00 AM – 12:00 PM ET
Citius Pharmaceuticals has officially crossed a major threshold.
After years as a development-stage biotech, the company has reported its first commercial revenue, following the U.S. launch of LYMPHIR, generating $3.9M in fiscal Q1 sales, in what can be viewed as a strategic inflection point.
Now the key question becomes: How does Citius scale from its initial oncology launch to deliver meaningful revenue visibility in 2026, and beyond?
Join Jason Kolbert, Head of Research at D. Boral Capital, for a live webinar with Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals, to discuss:
- Early LYMPHIR launch traction and physician adoption
- Commercial execution strategy in a rare oncology market
- Balance sheet positioning, including recent $3.8M non-dilutive funding
- Revenue ramp expectations into 2026 and 2027
- The role of Mino-Lok and Halo-Lido in portfolio diversification
- Strategic priorities as Citius transitions into a multi-asset commercial company
Citius is no longer just a pipeline story. It is now executing on its objectives as a commercial-stage oncology company with multiple late-stage assets.
If you follow emerging oncology platforms or commercial-stage biotech transitions, this fireside conversation is one you will not want to miss.